Alglucosidase Alfa

Glycogen Storage Disease II

Erasmus Medical Centerprotein_peptidePhase 4 / ApprovedActive

A

80/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 74/ 100
Competitive Position: 89/ 100

Competitive context

6 Active assets in the Glycogen Storage Disease II cohort.

Asset / Sponsor	Phase	Rating
Avalglucosidase Alfa Genzyme, a Sanofi Company	Phase 4	A
Albuterol National Taiwan University Hospital	Phase 4	BBB
Rituximab University of Florida	Phase 4	BB
METHOTREXATE National Taiwan University Hospital	Phase 4	BB
Bortezomib National Taiwan University Hospital	Phase 4	B

View all 26 →

Same molecule, other indications

Alglucosidase Alfa is also rated in:

glycogen storage disease due to acid maltase deficiency, late-onsetActive

BBB

Indicative · Phase 4

78 / 100

glycogen storage disease due to acid maltase deficiency, infantile onsetDormant

BB

Indicative · Phase 4

69 / 100

disorder of glycogen metabolismDormant

D

Indicative · Unknown

30 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.